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Abstract
Background: Polymorphism G1465A in the GABBR1 gene has been suggested as a risk factor for
non-lesional temporal lobe epilepsy (TLE); however, this genetic association study has not been
independently replicated. We attempted to replicate this study in our cohort of patients with TLE.
Furthermore, we also analyzed the coding sequence of this gene and searched for disease-causing
mutations.
Methods: We included 120 unrelated individuals with TLE that was preceded by febrile seizures
(FS) who did not have any evidence of structural lesions suggesting secondary epilepsy. 66
individuals had positive family history of TLE epilepsy and 54 were sporadic. Each patient was
genotyped for the presence of G1465A polymorphism. All exons of the GABBR1 gene were
screened by single strand confirmation polymorphism method. Genotypes were compared with
two independent matched control groups.
Results: We detected two A alleles of the G1465A polymorphism in one homozygous control
subject (0.87% of all alleles) and one A allele in a patient with TLE (0.45%, not significant). Other
detected polymorphisms in coding regions had similar frequencies in epilepsy patients and control
groups. No disease causing mutations in the GABBR1 gene were detected in patients with sporadic
or familial TLE.
Conclusion:  Our results indicate that TLE preceded by FS is not associated with the
polymorphisms or mutations in the GABBR1 gene, including the G1465A polymorphism. The
proportion of TLE patients with FS in the original study, reporting this positive association, did not
differ between allele A negative and positive cases. Thus, our failure to reproduce this result is likely
applicable to all non-lesional TLE epilepsies.
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Background
Temporal lobe epilepsy (TLE) preceded by febrile seizures
(FS) was historically considered to be an acquired disor-
der. However, recent studies have confirmed the existence
of distinct genetic syndromes encompassing both FS and
TLE [1,2]. Additionally, a positive history of FS in families
with temporal lobe epilepsy is more common than
expected by chance; this suggests that FS may be an initial
manifestation of some temporal lobe epileptic syndromes
[3-6]. The genetic etiology of TLE preceded by FS remains
unknown. Two loci for this condition have been mapped,
however, the causative genes have not been identified
[1,2].
γ -aminobutyric acid (GABA) is the main inhibitory neuro-
transmitter system in the brain. Mutations in the GABA-A
receptor subunit genes (GABRA), encoding products that
form a heteropentameric chloride channel, have been
identified as rare causes of idiopathic generalized epilep-
sies showing a Mendelian inheritance pattern [7]. How-
ever, mutations in the GABRAgenes have thus far not
appeared to be a major cause of TLE or other focal epilep-
sies [8].
The second, or B-subtype of GABA receptors (GABRB)
function by acting through G-protein coupled signaling
systems. Alteration in this GABA system during epilep-
togenesis is suggested from experimental data [9,10]. Fur-
thermore, a previously described variant (G1465A) in the
GABBR1 locus, encoding the GABRBβ 1 subunit has been
reported in association with TLE, including TLE preceded
by FS [11]. Genetic association studies are fraught with
many difficulties and independent replication is impor-
tant to establish the validity of any reported association
[12]. We report genetic analysis of GABBR1 gene by thor-
ough screening of GABBR1  exons for disease-causing
mutations, and attempted replication of association at the
G1465A polymorphism in a cohort of our patients exhib-
iting TLE preceded by FS.
Methods
Subjects
This study included 120 unrelated patients carrying a
diagnosis of TLE preceded by FS. Informed consent,
approved by the Institutional Review Board was obtained
from every subject enrolled. A TLE diagnosis was made
based on a history obtained from the patient and wit-
nesses, with particular attention to descriptions of aura
and complex partial seizure semiology, suggesting tempo-
ral lobe origin. Diagnoses were supported by electroen-
cephalograph (EEG) recordings and MRI neuroimaging;
some cases involved EEG-video recordings. MRI examina-
tion included 3D gradient echo imaging (Spoiled Gradi-
ent Recalled Acquisition) performed in the coronal plane
with the slice thickness 1 mm, FLAIR and T2-weighted
coronal sections; all coronal sections were perpendicular
to the long axis of the hippocampus. Additional MRI
sequences included T2-weighted axial and T1-weighted
sagittal brain images. Only subjects with a reliable clinical
classification were included in these studies.
Data collection involved age and duration at first FS, pres-
ence of any focal ictal or postictal features, total number
of FS, and age at FS remission. Information was obtained
from parents and/or older siblings. FS were classified as
complex if they lasted longer than 15 minutes, had focal
ictal or postictal features, or occurred more than once dur-
ing the same day. Detailed family histories were obtained
from all patients, including relatives with a history of epi-
lepsy, FS, or both. Information was obtained from all first-
degree relatives (mother, father, brothers, sisters, and chil-
dren); information regarding second-degree relatives
involved questions related to grandparents, grandchil-
dren, nieces, nephews, aunts and uncles.
Genetic analysis
DNA was isolated from peripheral blood from all subjects
and relevant affected and unaffected family members
enrolled in this study using standard methods. The cur-
rent study focused solely on affected probands. The
GABBR1 G1465A polymorphism was analyzed as previ-
ously described [13,14]. The PCR product was digested
overnight with EagI  restriction enzyme following the
manufacturer's protocol (New England Biolabs; Beverly,
MA). Products were analyzed by electrophoresis on 2%
agarose gels and subsequent visualization of resolved frag-
ments.
PCR primers flanking all exons were designed from pub-
lished sequence and public genomic assemblies covering
the locus (primer sequences are available upon request)
[15]. Exon screening was performed using single strand
confirmation polymorphism (SSCP) analysis; abnormal
mobility shifts were sequenced.
All polymorphisms identified, including G1465A, were
analyzed in two distinct ethnically- (Caucasians) and gen-
der-matched control samples. The first comparison group
consisted of DNA samples from 118 unrelated, healthy
subjects obtained from the Vanderbilt Center for Human
Genetics Research DNA Resource Core. The individuals
from this group were absent any family history of epi-
lepsy. The second control group corresponded to the Cau-
casian panel of 100 DNA samples from healthy
individuals purchased from the Coriell Cell Repositories
[16].
Statistical analysis
Allele frequencies comparisons between patient and con-
trol groups was determined using a chi-square test. Mann-BMC Medical Genetics 2005, 6:13 http://www.biomedcentral.com/1471-2350/6/13
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Whitney U test was used to compare demographic and
clinical characteristics between patients with epilepsy and
control subjects.
Results
The 120 case subjects enrolled in this study included 49
men and 71 women (average age 34.8 ± 14.9 years) with
a positive history of TLE, in which FS preceded the onset
of epilepsy. Average age of TLE onset was 22.81 ± 10.08
years, with an average syndromic duration of 12.65 ± 8.12
years. Positive family history of epilepsy was reported in
66 individuals, while 54 were apparently sporadic cases.
These two subgroups did not significantly differ in their
demographic composition; however, familial cases had a
significantly earlier age of epilepsy onset compared to
sporadic cases (13.64 ± 8.23 and 27.44 ± 11.78, p < 0.01).
All familial cases had at least one TLE affected relative in
either previous or successive generations, consistent with
vertical transmission of this trait. Medically refractory epi-
lepsy was present in 23 patients (19%).
Genotype analysis of the G1465A variant detected a single
A allele in one subject with TLE, who exhibited poor sei-
zure control in spite of optimal clinical management. This
patient had a positive family history of TLE and FS on one
parent's side of the family. Genotype analysis of both par-
ents indicated the A allele was present in the unaffected
parent from the other side of the family, and thus did not
segregate with disease. Two alleles of the same variant
were detected in the control group in one control subject
who was homozygous for this polymorphism. Allele fre-
quencies for case and control groups corresponded to
0.45% or 0.87%, respectively; p = 0.988). Genotype accu-
racy for G1465A was confirmed by combined sequence
and SSCP analyses that showed distinct and unambiguous
mobility shift patterns for both heterozygous and
homozygous states.
SSCP analysis of all coding exons did not reveal any
apparent disease-causing mutations in GABBR1. We did,
however, identify one previously described nonsynony-
mous variant (C59T) in exon 1, resulting in an alanine to
valine substitution in one patient. This known single
nucleotide polymorphism (SNP) is present in 1–3% of
normal subjects, and it has been reported in a
homozygous state in one affected individual [13]. Given
the known normative frequency of the C59T SNP
(rs#1805056), control samples were not screened. Several
SNPs were detected in exon 11, which also contains the
G1465A, variant, previously reported to be in exon 7 [11].
We detected three previously reported synonymous
(silent) sequence changes – T1473C (rs#N/A), T1476C
(rs#N/A), and T1485C (rs#29225) [14]. They appeared to
be present on the same haplotype, based on segregation
analysis of carrier relatives with this allele and constant
SSCP mobility shift patterns. The frequency of this three-
SNPs haplotype was determined to be 10.83% (26/240,
including one homozygous individual); there was no dif-
ference between sporadic and familial cases. Analysis of
controls (236 chromosomes) initially detected an allele
infrequency of 4.23%, suggesting a significant trend (p <
0.05). Subsequent analysis of the second control sample
identified a frequency very similar to the TLE patient sam-
ple (18/200, 9%, p = 0.63). Finally, we identified several
novel intronic SNPs not predicted to alter splicing, and
their frequency did not differ significantly between the
TLE and control samples (data not shown).
Discussion
The 1465A allele at GABBR1 was proposed as a potential
risk factor for TLE, particularly in patients with medically
refractory seizures [11]. We were unable to replicate this
result, and no association of this allele with TLE was
detected in our cohort of patients. Furthermore, system-
atic screening of all GABBR1 exons did not identify any
obvious disease-related variants or novel SNPs or haplo-
types significantly associated with the development of
TLE.
The conflicting results between our study and that
reported by Gambardella et al, [11] are unlikely due to
clinical differences in the subject population or insuffi-
cient power. The sample sizes were similar (120 in our
study and 141 in the original report [11]) in both studies.
Our cohort had a history of antecedent FS, due to our
ongoing effort to characterize this TLE subtype. The sam-
ples analyzed by Gambardella et al.[11] were mixed in
this regard, and included patients with and without FS.
Only 14.8% of their patients had a positive history of
febrile convulsions, but the presence or absence of an FS
history did not correlate with carrier status of the 1465A
allele (16.7% with vs. 14.5% without 1465A) [11]. Our
patient sample was more heavily loaded towards those
with positive family history (55%) when compared with
the study by Gambardella and colleagues [11] whose
patient samples comprised of 36.2% of patients with a
family history of epilepsy.
The control 1465A allele frequency in the current study
was somewhat higher than in the previous study (0.87%
vs. 0.26%, respectively), however, the difference between
these two populations is not significant. This is consistent
with other studies that found <1% frequency for the
1457A variant with an exception of one report, which
identified 10% frequency of this allele in a cohort of 50
patients [11,13,14]. Our results support the conclusion
that G1465A is a rare polymorphism. We also verified the
presence of G1465A polymorphism by SSCP and
sequencing and we had a complete agreement betweenBMC Medical Genetics 2005, 6:13 http://www.biomedcentral.com/1471-2350/6/13
Page 4 of 5
(page number not for citation purposes)
different methods, arguing against incorrect genotyping as
an explanation of our negative finding.
A systemic screening of all exons at the GABBR1 locus
identified alleles at three known SNPs in exon 11 that also
contains the 1465A variant, thus defining a unique haplo-
type [14]. These sequence changes are silent without any
amino acid change in the protein. The comparison of the
haplotypic frequency with our first control group sug-
gested a potential increase, although a plausible function-
ality is currently unclear. The nonreplication in the second
control group leaves the initial trend in doubt, and com-
pels a conservative interpretation.
Spurious association that cannot be subsequently repli-
cated can be caused by several factors [17]. Other than an
inadequate sample size, selection bias is probably the
most likely explanation of discrepancies between associa-
tion studies. Unrecognized population stratification has
been detected even in studies with otherwise proper
design [18]. The problem of population stratification
despite a careful selection is also demonstrated by the dif-
ferences between the frequencies of the 1465A variant
between our two control groups. It has been suggested
that two control groups should be used in association
studies, one population-based and one family based [19].
We did not have a family-based control group available
but our conflicting data between two independent popu-
lation-based control groups suggest that this approach is
also useful in confirmation of true genetic association.
Conclusion
Our data suggest that variants in GABBR1 are not signifi-
cantly involved in the pathogenesis of TLE preceded by FS.
The proportion of TLE patients with FS in the original
study, which reported this positive association did not dif-
fer between allele A negative and positive cases, and thus
our failure to reproduce this result is likely applicable to
all non-lesional TLE epilepsies.
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